Decoy Therapeutics, Inc. (DCOY)
3.11
-0.09
(-2.81%)
USD |
NASDAQ |
Aug 24, 16:00
3.11
0.00 (0.00%)
After-Hours: 20:00
Decoy Therapeutics Enterprise Value : -6.635M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -6.635M |
| August 21, 2026 | -6.587M |
| August 20, 2026 | -6.544M |
| August 19, 2026 | -6.475M |
| August 18, 2026 | -6.337M |
| August 17, 2026 | -6.416M |
| August 14, 2026 | -6.384M |
| August 13, 2026 | -6.411M |
| August 12, 2026 | -6.374M |
| August 11, 2026 | -6.230M |
| August 10, 2026 | -6.252M |
| August 07, 2026 | -6.198M |
| August 06, 2026 | -6.129M |
| August 05, 2026 | -6.06M |
| August 04, 2026 | -5.964M |
| August 03, 2026 | -5.980M |
| July 31, 2026 | -6.103M |
| July 30, 2026 | -6.204M |
| July 29, 2026 | -6.145M |
| July 28, 2026 | -6.140M |
| July 27, 2026 | -6.299M |
| July 24, 2026 | -5.608M |
| July 23, 2026 | -5.661M |
| July 22, 2026 | -5.656M |
| July 21, 2026 | -5.672M |
| Date | Value |
|---|---|
| July 20, 2026 | -5.467M |
| July 17, 2026 | -5.305M |
| July 16, 2026 | -5.102M |
| July 15, 2026 | -5.001M |
| July 14, 2026 | -5.230M |
| July 13, 2026 | -5.182M |
| July 10, 2026 | -5.145M |
| July 09, 2026 | -4.956M |
| July 08, 2026 | -5.230M |
| July 07, 2026 | -4.554M |
| July 06, 2026 | -4.432M |
| July 02, 2026 | -4.400M |
| July 01, 2026 | -4.235M |
| June 30, 2026 | -4.464M |
| June 29, 2026 | -2.719M |
| June 26, 2026 | -4.885M |
| June 25, 2026 | -4.672M |
| June 24, 2026 | -4.570M |
| June 23, 2026 | -4.629M |
| June 22, 2026 | -4.469M |
| June 18, 2026 | -4.591M |
| June 17, 2026 | -4.655M |
| June 16, 2026 | -4.692M |
| June 15, 2026 | -4.575M |
| June 12, 2026 | -4.623M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Palatin Technologies, Inc. | 8.174M |
| Unicycive Therapeutics, Inc. | 88.06M |
| Nuvectis Pharma, Inc. | 615.04M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.374M |
| Revenue (Quarterly) | 0.2276M |
| Total Expenses (Quarterly) | 2.601M |
| EPS Diluted (Quarterly) | -4.462 |
| Gross Profit Margin (Quarterly) | 94.02% |
| Profit Margin (Quarterly) | -1.04K% |
| Earnings Yield | -1.52K% |
| Normalized Earnings Yield | -1160.02 |